GlassScriptPhysician profile
Andrew Thuc Truong
NPI 1134513047
$9,786.38
in general payments reported to CMS, 2019-2025
52 companies · $953 in 2025
The $953 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $1,590 · 2021: $2,077 · 2022: $2,202 · 2023: $1,040 · 2024: $1,017 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,284.65 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,154.43 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $922.99 | 2019-2024 | Qulipta, Vraylar, Linzess |
| Novartis Pharmaceuticals Corporation | $746.78 | 2019-2025 | |
| Novo Nordisk INC | $675.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $561.32 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $396.17 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $289.73 | 2019-2025 | Farxiga |
| Pfizer INC. | $269.41 | 2019-2025 | |
| Gilead Sciences, INC. | $255.50 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.99 | 2021 | |
| Shield Therapeutics INC | $210.50 | 2022-2023 | Accrufer |
| Amarin Pharma, INC. | $195.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $188.25 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Antares Pharma, INC. | $187.08 | 2020-2023 | Nocdurna, Tlando, Xyosted |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.